Name: UMIN ID:
Unique ID issued by UMIN | UMIN000014649 |
---|---|
Receipt number | R000016961 |
Scientific Title | A randomized, multicenter, phase II trial comparing neo-adjuvant therapy using pertuzumab and trastuzumab emtansine based on the dual HER2 blockade in patients with operable HER2-positive primary breast cancer(Neo-peaks study) |
Date of disclosure of the study information | 2014/08/01 |
Last modified on | 2021/07/30 11:15:28 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2014/07/25 18:21:01 | ||
2 | Update | 2014/07/25 18:26:24 | UMIN ID1 UMIN ID2 |
|
3 | Update | 2014/07/26 18:54:27 | Division name |
|
4 | Update | 2014/07/26 18:57:05 | IND to MHLW |
|
5 | Update | 2014/07/26 19:02:14 | IND to MHLW |
|
6 | Update | 2014/07/26 19:03:02 | IND to MHLW |
|
7 | Update | 2014/07/28 18:59:25 | IND to MHLW |
|
8 | Update | 2014/07/31 15:48:50 | Key inclusion criteria Key exclusion criteria Key exclusion criteria |
|
9 | Update | 2014/08/13 14:09:07 | Narrative objectives1 Primary outcomes Key secondary outcomes |
|
10 | Update | 2014/08/13 17:20:27 | Key inclusion criteria Key exclusion criteria |
|
11 | Update | 2014/08/13 17:21:19 | Recruitment status |
|
12 | Update | 2016/05/23 17:10:22 | Recruitment status |
|
13 | Update | 2016/05/23 17:12:30 | Name of primary person or sponsor Organization Institutions |
|
14 | Update | 2016/07/27 15:18:22 | Last follow-up date |
|
15 | Update | 2018/01/26 09:53:33 | Key inclusion criteria Key inclusion criteria Key exclusion criteria |
|
16 | Update | 2018/08/23 17:43:09 | Public title |
|
17 | Update | 2018/08/24 10:09:50 | UMIN ID1 UMIN ID2 |
|
18 | Update | 2019/09/05 15:08:09 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Address Last name of contact person Last name of contact person Zip code Address Address Organization Organization Address Address Tel |
|
19 | Update | 2019/09/05 15:10:54 | Number of participants that the trial has enrolled |
|
20 | Update | 2019/09/05 15:15:18 | Date of IRB |
|
21 | Update | 2021/06/16 15:11:38 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Organization Organization Division name Division name Name of person sending information Name of person sending information Organization Division name Institute |
|
22 | Update | 2021/06/16 15:24:41 | Homepage URL |
|
23 | Update | 2021/07/30 11:15:28 | Recruitment status |